Jonathan C. Trent, MD, PhD

Articles

Dr. Trent on the Role of Avapritinib in PDGFRA Exon 18+ GIST

April 9th 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Dr. Trent on the Potential Role of Immunotherapy in GIST

November 19th 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Dr. Trent on the Impact of COVID-19 on the Treatment of Rare Cancers

May 12th 2020

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Dr. Trent on Research Efforts in Bone and Soft Tissue Sarcomas

May 1st 2020

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Streamlining the Precision Medicine Process: It's Possible, Necessary, and Improves Care

May 28th 2017

Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.

Dr. Jonathan Trent on Pembrolizumab in Advanced Sarcomas

August 9th 2016

Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

July 9th 2016

Treating Bone and Soft Tissue Sarcomas

October 16th 2015

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.